Identifying and Characterizing Preclinical MS
DREAM
1 other identifier
observational
1,000
1 country
1
Brief Summary
The purpose of this research study is to try and identify risk factors and biologic changes that suggest that someone may go on to develop multiple sclerosis before a person has shown any symptoms of the disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 21, 2022
CompletedFirst Submitted
Initial submission to the registry
March 15, 2023
CompletedFirst Posted
Study publicly available on registry
March 28, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2032
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2033
November 14, 2025
November 1, 2025
10 years
March 15, 2023
November 12, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
To build a machine learning model of risk prediction
to build a risk prediction model that estimates future risk of MS built using large datasets of biologic and clinical data collected during the study.
ongoing prospective study
Secondary Outcomes (1)
Individual data types collected
ongoing prospective study
Interventions
blood draw, oral swab, optional stool samples, spinal fluid sample, fat biopsy, tonsil biopsy, lymph node tissue sample, MRI
Eligibility Criteria
Individuals with risk factors for MS (based on personal demographics, past medical history, or family history) will be recruited to provide clinical information and biospecimens serially over time.
You may qualify if:
- Age 18+
- Having one or more risk factors for multiple sclerosis, including one or more of the below:
- Individuals known to have a radiologically isolated syndrome
- Individuals with a family history of multiple sclerosis (first degree family member)
- Individuals with personal risk factors, which are known to include smoking, obesity, Epstein Barr virus infections, Vitamin D deficiency, genetic risk score
You may not qualify if:
- Currently pregnant
- Diagnosis of multiple sclerosis or any ongoing, systemic autoimmune disease
- Ongoing treatment with immunosuppressive medications
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Yale Universitylead
- Roche-Genentechcollaborator
Study Sites (1)
Yale University
North Haven, Connecticut, 06473, United States
Biospecimen
blood and gingival swabs
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Erin Longbrake, MD
Yale University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 15, 2023
First Posted
March 28, 2023
Study Start
June 21, 2022
Primary Completion (Estimated)
June 30, 2032
Study Completion (Estimated)
June 30, 2033
Last Updated
November 14, 2025
Record last verified: 2025-11